Table 2.

Single-agent therapies in clinical trials

Inhibitor	Biomarker	Cancer type	CRC patients enrollment	Phase	NCT number	Status
KRASG12C inhibitors
AMG 510	KRASG12C mutation	Advanced solid tumors	Enrolled	I/II	NCT03600883	Recruiting
MRTX849	KRASG12C mutation	Advanced solid tumors	Enrolled	I/II	NCT03785249	Recruiting
JNJ-74699157	KRASG12C mutation	Advanced solid tumors	Enrolled	I	NCT04006301	Completed
LY3499446	KRASG12C mutation	Advanced solid tumors	Enrolled	I/II	NCT04165031	Terminated
SOS inhibitors
BI 1701963	KRAS mutations	Advanced solid tumors	Not mentioned	I	NCT04111458	Recruiting
SHP2 inhibitors
RMC-4630	Mutations that hyperactive the RAS-MAPK pathway	Relapsed or refractory solid tumors	Not mentioned	I	NCT03634982	Recruiting
RAF inhibitors
LY3009120	BRAF, NRAS or KRAS mutations	Advanced or metastatic solid tumors	Enrolled	I	NCT02014116	Terminated
BGB-283	BRAF, NRAS or KRAS mutations	Advanced solid tumors	Enrolled	I	NCT02610361	Completed
ERK inhibitors
GDC-0994	BRAF or KRAS mutations	Advanced or metastatic solid tumors	Enrolled	I	NCT01875705	Completed
BVD-523	NRAS, HRAS, KRAS, BRAF, MEK or ERK mutations	Advanced MAPK pathway-altered malignancies	Enrolled	I	NCT04566393	Available
Adoptive cell therapies
Anti-KRAS G12D mTCR	HLA-A*11:01 positive KRASG12D mutation	Advanced solid tumors	Enrolled	I/II	NCT03745326	Suspended
Anti-KRAS G12V mTCR	HLA-A*11:01 positive KRASG12D mutation	Advanced solid tumors	Enrolled	I/II	NCT03190941	Suspended
Cancer vaccines
TG02	KRAS exon 2, codon 12 or 13 mutation	Rectal cancer	Enrolled	I	NCT02933944	Terminated
mRNA-5671	KRASG12D, KRASG12V, KRASG12C, KRASG13D mutation	NSCLC, non-MSI-H CRC, PDAC	Enrolled	I	NCT03948763	Recruiting

Abbreviations: CRC colorectal cancer, NSCLC non-small cell lung cancer, PDAC pancreatic ductal adenocarcinoma, MSI-H microsatellite instability-high, TCR T-cell receptor, HLA human leukocyte antigen. Data acquired from ClinicalTrials.gov